Skip to main content

Table 2 Correlation between S1PR1/pSTAT3 expression and clinicopathologic variables

From: Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas

variables

S1PR1

pSTAT3

 

Negative

Positive

Total

P*

Negative

Positive

Total

P*

Age, years

        

 Mean (range)

        

 <60

30 (48%)

20 (49%)

50 (49%)

0.969

21 (50%)

29 (48%)

50 (49%)

0.806

 ≥60

32 (52%)

21 (51%)

53 (51%)

 

21 (50%)

32 (52%)

53 (51%)

 

Sex

        

 Male

34 (55%)

29 (67%)

61 (59%)

0.265

28 (67%)

33 (54%)

61 (59%)

0.202

 Female

28 (45%)

14 (33%)

42 (41%)

 

14 (33%)

28 (46%)

42 (41%)

 

Primary nodal disease

        

 Nodal

27 (44%)

10 (24%)

37 (36%)

0.047†

21 (50%)

16 (26%)

37 (36%)

0.013†

 Extranodal

35 (56%)

31 (76%)

66 (64%)

 

21 (50%)

45 (74%)

66 (64%)

 

Primary UAT disease

        

 Non-UAT

55 (89%)

28 (68%)

83 (81%)

0.010†

39 (93%)

44 (72%)

83 (81%)

0.009†

 UAT

7 (11%)

13 (32%)

20 (19%)

 

3 (7%)

17 (28%)

20 (19%)

 

Ann Arbor stage

        

 I, II

26 (42%)

21 (51%)

47 (46%)

0.354

18 (43%)

29 (48%)

47 (46%)

0.639

 III, IV

36 (58%)

20 (49%)

56 (54%)

 

24 (57%)

32 (52%)

56 (54%)

 

IPI group‡

        

 Low (0–2)

36 (61%)

24 (65%)

60 (63%)

0.705

23 (59%)

37 (65%)

60 (63%)

0.555

 High (3–5)

23 (39%)

13 (35%)

36 (37%)

 

16 (41%)

20 (35%)

36 (37%)

 

B symptoms‡

        

 Absent

46 (76%)

31 (78%)

77 (76%)

0.809

36 (86%)

41 (69%)

77 (76%)

0.059

 Present

15 (24%)

9 (22%)

24 (24%)

 

6 (14%)

18 (31%)

24 (24%)

 

ECOG PS‡

        

 0, 1

54 (87%)

32 (80%)

86 (84%)

0.336

36 (86%)

50 (83%)

86 (84%)

0.745

 ≥2

8 (13%)

8 (20%)

16 (16%)

 

6 (14%)

10 (17%)

16 (16%)

 

LDH‡

        

 Normal

25 (43%)

18 (47%)

43 (45%)

0.681

16 (42%)

27 (47%)

43 (45%)

0.668

 Elevated

33 (57%)

20 (53%)

53 (55%)

 

22 (58%)

31 (53%)

53 (55%)

 

BM involvement‡

        

 Absent

56 (90%)

29 (78%)

85 (86%)

0.099

38 (95%)

47 (80%)

85 (86%)

0.032†

 Present

6 (10%)

8 (22%)

14 (14%)

 

2 (5%)

12 (20%)

14 (14%)

 

Number of extranodal sites

        

 0, 1

45 (73%)

30 (73%)

75 (73%)

0.947

30 (71%)

45 (74%)

75 (73%)

0.793

 ≥2

17 (27%)

11 (27%)

28 (27%)

 

12 (29%)

16 (26%)

28 (27%)

 

EBER‡

        

 Negative

58 (94%)

37 (95%)

95 (94%)

0.784

39 (93%)

56 (95%)

95 (94%)

0.666

 Positive

4 (6%)

2 (5%)

6 (6%)

 

3 (7%)

3 (5%)

6 (6%)

 

Hans classification‡

        

 GCB

24 (40%)

13 (33%)

37 (37%)

0.503

21 (53%)

16 (27%)

37 (37%)

0.010†

 Non-GCB

36 (60%)

26 (67%)

62 (63%)

 

19 (47%)

43 (73%)

62 (63%)

 

pSTAT3 nuclear expression

        

 Negative

28 (45%)

14 (34%)

42 (41%)

0.265

-

-

-

-

 Positive

34 (55%)

27 (66%)

61 (59%)

 

-

-

-

 

Total

62 (100%)

41 (100%)

103 (100%)

 

42 (100%)

61 (100%)

103 (100%)

 
  1. DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell like; ABC, activated B-cell like; IPI, international prognostic index; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; BM, bone marrow; EBER, EBV-encoded RNA; UAT, upper aerodigestive tract. *P values were calculated using Pearson’s chi-square test. †indicates P values are less than 0.05. ‡The number excludes missing values.